Welcome to our dedicated page for ONWARD Medical NV news (Ticker: ONWRY), a resource for investors and traders seeking the latest updates and insights on ONWARD Medical NV stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ONWARD Medical NV's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ONWARD Medical NV's position in the market.
ONWARD Medical (OTCQX: ONWRY), a neurotechnology company focused on restoring movement and function in spinal cord injury patients, has announced significant changes to its Board of Directors. Professor Tim Denison, a distinguished neurotechnology expert from the University of Oxford and former Medtronic VP, joins the Board, replacing Co-Founder Professor Gregoire Courtine.
Denison brings extensive expertise as a Professor of Clinical Neurosciences, Fellow of prestigious engineering academies, and co-founder of Amber Therapeutics. Professor Courtine will transition from his Board role to focus on his new position as Director of the Neuro-X Institute but will continue serving as Science Advisor to ONWARD.
The company also confirmed several other Board appointments, including the reappointment of Dave Marver as CEO and the formal ratification of Rob ten Hoedt as Chairman.
ONWARD Medical (OTCQX: ONWRY) has announced two major regulatory submissions for its ARC-EX System, a breakthrough therapy for spinal cord injury (SCI) patients. The company has filed a 510(k) application with the FDA seeking clearance for home use expansion in the United States, where it is currently the only FDA-cleared technology for improving hand sensation and strength after SCI.
In parallel, ONWARD has submitted a CE Mark application under the European Union Medical Device Regulation (MDR) to enable commercialization in the EU and other countries recognizing CE Marking. These submissions, completed in June 2025, follow the successful initial phase of the US clinical launch and strong early demand.
Supporting these applications, the company recently published positive results from the Pathfinder2 Study in Neuromodulation: Technology at the Neural Interface. The one-year trial demonstrated significant functional improvements in participants, including enhanced upper body strength, trunk control, and balance, with no plateau in therapeutic benefits when ARC-EX Therapy was combined with activity-based rehabilitation.
ONWARD Medical, a medical technology company specializing in spinal cord stimulation therapies, has announced its 2025 Annual General Meeting (AGM) scheduled for June 11, 2025, in Amsterdam. The company, trading as ONWD on Euronext and ONWRY on US OTCQX, will present twelve key voting items.
The agenda includes crucial resolutions such as:
- Adoption of 2024 financial accounts
- Compensation policy approval
- Re-appointment of key directors including David Marver and Ian Curtis
- New appointments of Rahma Samow and Robert ten Hoedt
- Authorization for share issuance up to 10% and 50% of capital
The record date is set for May 14, 2025. All AGM materials are available on the company's investor relations website, with US ADR holders receiving notice through Bank of New York Mellon.
ONWARD Medical N.V. (Euronext: ONWD), a medical technology company specializing in spinal cord stimulation therapies, has filed its 2024 Annual Report with the Dutch Authority for the Financial Markets (AFM). The company, which focuses on restoring movement and independence for people with spinal cord injury (SCI), has also published its 2024 Sustainability Report.
The company received recognition for its sustainability efforts in 2024, earning a silver medal from EcoVadis, the world's largest business sustainability ratings provider. CEO Dave Marver described 2024 as a transformative year for ONWARD in advancing their mission.
Stakeholders can access the 2024 Annual Report, Sustainability Summary, and a recording of the 2024 Full Year Results Webinar from April 1, 2025, on the company's Investor Relations webpage.
ONWARD Medical (Euronext: ONWD, OTCQX: ONWRY) has established a sponsored Level 1 American Depositary Receipt (ADR) program in the United States through the Bank of New York Mellon (BNY), with ADRs now trading on the OTCQX® Best Market under symbol ONWRY.
The medical technology company, which develops spinal cord stimulation therapies for movement restoration, aims to enhance US investor access through this program. One ONWARD ADR represents one ordinary share and is denominated in US dollars, making it easier for American investors to trade.
The ADR program and OTCQX upgrade are designed to broaden ONWARD's shareholder base and increase stock liquidity. BNY will serve as the depositary bank and transfer agent for the ADR program, with US investors able to access financial disclosure and Real-Time Level 2 quotes on otcmarkets.com.
FAQ
What is the current stock price of ONWARD Medical NV (ONWRY)?
